Advancing Vaccines
For Better Lives

Welcome to Valneva

We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Our focused pipeline includes the world’s first vaccine against the chikungunya virus, the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, as well as vaccine candidates against the Zika virus and other global public health threats.

Learn More

Check out our 2022 Annual Business Report

Learn More

Follow Us

🔴 Today is #WorldEncephalitisDay and we are proud to help @Encephalitis International bring awareness to this serious condition.
To learn more, please visit https://www.encephalitis.info/
#WED #Red4WED

🔴 Today, we are going #Red4WED, bringing attention to the devastating condition of #encephalitis on #WorldEncephalitisDay.
Visit our charitable partner @Encephalitis International for more information: https://www.encephalitis.info/

Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance
https://valneva.com/press-release/valneva-reports-full-year-2023-revenue-and-cash-provides-first-2024-guidance

Load More